CYTOMED THERAPEUTICS LTD (GDTC) Stock Price, Forecast & Analysis
USA - NASDAQ:GDTC - SGXZ17669631 - Common Stock
GDTC Key Statistics, Chart & Performance
The current stock price of GDTC is 1.97 USD. In the past month the price decreased by -23.35%. In the past year, price decreased by -12.81%.
GDTC Latest News, Press Relases and Analysis
GDTC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.75 | 413.16B | ||
| AMGN | AMGEN INC | 15.66 | 184.43B | ||
| GILD | GILEAD SCIENCES INC | 15.43 | 156.76B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.4 | 108.61B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.75 | 75.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 901.25 | 60.25B | ||
| INSM | INSMED INC | N/A | 42.53B | ||
| NTRA | NATERA INC | N/A | 29.48B | ||
| BIIB | BIOGEN INC | 10.01 | 24.57B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.03 | 21.52B | ||
| INCY | INCYTE CORP | 15.68 | 19.66B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 32.84 | 13.62B |
Related stock screener links
About GDTC
Company Profile
CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. The company is focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and gamma delta Natural Killer T cel to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT, and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The CTM-GDT product candidate consists of expanded allogeneic gamma delta T cells.
Company Info
CYTOMED THERAPEUTICS LTD
#08-22 One Commonwealth, 1 Commonwealth Lane
Singapore SG
Employees: 43
Phone: 65603824911
CYTOMED THERAPEUTICS LTD / GDTC FAQ
Can you describe the business of CYTOMED THERAPEUTICS LTD?
CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. The company is focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and gamma delta Natural Killer T cel to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT, and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The CTM-GDT product candidate consists of expanded allogeneic gamma delta T cells.
What is the stock price of CYTOMED THERAPEUTICS LTD today?
The current stock price of GDTC is 1.97 USD.
What is the dividend status of CYTOMED THERAPEUTICS LTD?
GDTC does not pay a dividend.
What is the ChartMill rating of CYTOMED THERAPEUTICS LTD stock?
GDTC has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for CYTOMED THERAPEUTICS LTD?
CYTOMED THERAPEUTICS LTD (GDTC) operates in the Health Care sector and the Biotechnology industry.
Should I buy GDTC stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GDTC.
What is the employee count for GDTC stock?
CYTOMED THERAPEUTICS LTD (GDTC) currently has 43 employees.
GDTC Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to GDTC. When comparing the yearly performance of all stocks, GDTC is a bad performer in the overall market: 60.02% of all stocks are doing better.
GDTC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GDTC. GDTC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GDTC Financial Highlights
Over the last trailing twelve months GDTC reported a non-GAAP Earnings per Share(EPS) of -0.24. The EPS decreased by -19.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.94% | ||
| ROE | -51.38% | ||
| Debt/Equity | 0.06 |
GDTC Forecast & Estimates
7 analysts have analysed GDTC and the average price target is 5.1 USD. This implies a price increase of 158.88% is expected in the next year compared to the current price of 1.97.
For the next year, analysts expect an EPS growth of -13.33% and a revenue growth -8.93% for GDTC